The financing will support Ensoma's recently initiated Phase 1/2 clinical trial for EN-374 in X-linked chronic granulomatous disease (X-CGD) and support key clinical readouts, while continuing to expand and refine the potential global impact of the company's in vivo engineered cell therapy platform in immuno-oncology and sickle cell disease.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

75 Kneeland St. 14th Floor
Boston, MA 02111
USA

Phone

Undisclosed

Website

www.ensoma.com

Email Address

[email protected]

Overview

At Ensoma, we believe every person, no matter where they are in the world, should have access to innovative technologies that are changing the way we treat disease. Harnessing the power of our Engenious vectors, we can deliver, for the first time, in vivo stem cell modification technologies without the need for prior conditioning or stem cell collection.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Paula Soteropoulos

Chief Executive Officer

Kush Parmar

Chief Scientific Officer

Robert Peters

Chief Technical Officer

Daniel Leblanc

VP - Bus. Development

Naina Bhasin

VP - Regulatory Affairs

Patrick Au

Browse more venture capital transactions:

Prev: 9/22/2025: SuperCom venture capital transaction
Next: 9/22/2025: Sisuta venture capital transaction

Share this article

About Our VC Transactions Data

We do our best to record every notable VC transaction. VC transactions on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary